Skip to main content
. Author manuscript; available in PMC: 2014 Feb 12.
Published in final edited form as: ACS Nano. 2012 Oct 30;6(11):9485–9495. doi: 10.1021/nn302317j

Figure 4.

Figure 4

Representative fluorescence emission spectra of non-crosslinked FRET based nanoparticles (FRET-NCMN1, DiO and rhodamine B pair) (a) and disulfide crosslinked FRET nanoparticles (FRET-DCMN1, DiO and rhodamine B pair) (b) in the presence of human plasma, respectively. The final concentrations of the nanoparticles were 0.1 mg/mL; the time-resolved apparent FRET efficiency (Eapp) change of FRET-NCMN1 (DiO and rhodamine B pair), FRET-NCMN2 (DiO and DiI pair), FRET-NCMN3 (FITC and rhodamine B pair), FRET-DCMN1 (DiO and rhodamine B pair) in human plasma and PBS (c), the apparent FRET efficiency is calculated as Eapp = IA/(IA + ID), where IA and ID represent acceptor and donor intensities, respectively; the time-resolved Eapp change of FRET-DCMN1 (DiO and rhodamine B pair) in the presence of human plasma and reducing agents (glutathione (GSH) and N-acetylcysteine (NAC)) (d); the time-resolved Eapp change of FRET-NCMN1 (DiO and rhodamine B pair) (e) and FRET-DCMN1 (DiO and rhodamine B pair) (f) in the presence of HSA (50 mg/mL), LDL (2.0 mg/mL), HDL (2.0 mg/mL), VLDL (1.0 mg/mL), CM (1.0 mg/mL) and IgG (10 mg/mL). Excitation: 480 nm. Values reported are the mean diameter ± SD for triplicate samples.